Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response

Autor: Jun Zhai, Carol R. Reed, Benjamin A. Salisbury, Chad Messer, Geoffrey S. Ginsburg, Deepak Voora, Svati H. Shah, David R. Crosslin
Rok vydání: 2008
Předmět:
Male
Simvastatin
Atorvastatin
Apolipoprotein E3
chemistry.chemical_compound
Gene Frequency
Hyperlipidemia
Genetics (clinical)
Pravastatin
Genetics
biology
Anticholesteremic Agents
Middle Aged
HMG-CoA reductase
Regression Analysis
Female
lipids (amino acids
peptides
and proteins)

Cardiology and Cardiovascular Medicine
ATP Binding Cassette Transporter 1
medicine.drug
Adult
medicine.medical_specialty
Statin
Adolescent
Genotype
medicine.drug_class
Hyperlipidemias
Polymorphism
Single Nucleotide

Article
Internal medicine
medicine
Humans
Genetic Predisposition to Disease
Pyrroles
Allele frequency
Alleles
Aged
Dose-Response Relationship
Drug

Cholesterol
Cholesterol
LDL

medicine.disease
Minor allele frequency
Endocrinology
Haplotypes
chemistry
Heptanoic Acids
biology.protein
ATP-Binding Cassette Transporters
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Zdroj: Circulation: Cardiovascular Genetics. 1:100-106
ISSN: 1942-3268
1942-325X
DOI: 10.1161/circgenetics.108.795013
Popis: Background— There is interindividual variation in low-density lipoprotein cholesterol (LDLc) lowering by statins and limited study into the genetic associations of the dose dependant LDLc lowering by statins. Methods and Results— Five hundred nine patients with hyperlipidemia were randomly assigned atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 10 mg (low-dose phase) followed by 80 mg, 80 mg, and 40 mg (high-dose phase), respectively. Thirty-one genes in statin, cholesterol, and lipoprotein metabolism were sequenced and 489 single nucleotide polymorphisms with minor allele frequencies >2% were tested for associations with percentage LDLc lowering at low doses using multivariable adjusted general linear regression. Significant associations from the analysis at low dose were then repeated at high-dose statins. At low doses, only 1 single nucleotide polymorphism met our experiment-wide significance level, ABCA1 rs12003906. Twenty-six subjects carried the minor allele of rs12003906, which was associated with an attenuated LDLc reduction (LDLc reduction in carriers versus noncarriers −24.1�2.6% versus −32.2�1.5%; P =0.0001). In addition, we replicated the association with the APOE ε3 allele and a reduced LDLc reduction. At high doses, carriers of the minor allele of ABCA1 rs12003906 and the APOE ε3 allele improved their LDLc reduction but continued to have a diminished LDLc reduction compared with noncarriers (−30.5�4.0% versus −42.0�2.4%; P =0.005) and (−38.5�1.9% versus −45.3�2.8%; P =0.009), respectively. Conclusions— An intronic single nucleotide polymorphism in ABCA1 and the APOE ε3 allele are associated with reduced LDLc lowering by statins and identify individuals who may be resistant to maximal LDLc lowering by statins.
Databáze: OpenAIRE